Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Richard D Weiner, MD, PhD
Duke University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Yale University
New Haven, Connecticut, United States
- Andrew Goddard, Md
Indianapolis, Indiana, United States
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Casewestern Reserve University
Cleveland, Ohio, United States
- Baylor College of Medicine
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2015
- Primary completion
- 1 Nov 2017
- Completion
- 1 Dec 2017
- Last update posted
- 8 Jan 2019
- Registered enrollment
- 163
- Registry id
- NCT02218736
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.